Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.

American journal of clinical oncology - 1 Aug 2014

Ragusa Mark, Vannucci Jacopo, Ludovini Vienna, Bianconi Fortunato, Treggiari Stefano, Tofanetti Francesca R, Flacco Antonella, Colella Renato, Sidoni Angelo, Crinò Lucio, Puma Francesco

Abstract excerpt

OBJECTIVES: Surgery yields best results for non-small cell lung cancer (NSCLC) patients. Epidermal growth factor receptor (EGFR) and its downstream factor Kirsten rat sarcoma viral oncogene homolog (KRAS) are variably mutated in NSCLC. Such mutations predict clinical response to tyrosine kinase i...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Smoking

Source

Identifiers

PMID: 23357969
DOI: 10.1097/COC.0b013e31827a7e7a

Genes

KRAS
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23357969-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.PMID 23357969Read ↗

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.Semantic proximity Read ↗

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.Semantic proximity Read ↗

KRAS mutations in lung cancer.Semantic proximity Read ↗

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.Semantic proximity Read ↗

Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.Semantic proximity Read ↗

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the LungSemantic proximity Read ↗

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.Semantic proximity Read ↗

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Semantic proximity Read ↗

KRAS mutations in non-small cell lung cancer.Semantic proximity Read ↗

Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society.Semantic proximity Read ↗

Clinicopathological features of lung adenocarcinoma with KRAS mutations.Semantic proximity Read ↗

[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.